Ignite Creation Date:
2024-05-05 @ 5:25 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00441376
Status:
COMPLETED
Last Update Posted:
2019-02-07
First Post:
2007-02-26
Brief Title:
A Study of ThermoDox in Combination With Radiofrequency Ablation RFA in Primary and Metastatic Tumors of the Liver
Sponsor:
Imunon
Organization:
Imunon
Study Overview
Official Title:
A Phase I Dose Escalation Tolerability Study of ThermoDox Thermally Sensitive Liposomal Doxorubicin in Combination With Radiofrequency Ablation RFA of Primary and Metastatic Tumors of the Liver
Status:
COMPLETED
Status Verified Date:
2019-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine the maximum tolerated dose MTD of ThermoDox when used in combination with radiofrequency ablation RFA in the treatment of primary and metastatic tumors of the liver
Detailed Description:
Ablative treatment approaches such as RFA or microwave ablation have received increased attention as alternates to other treatment approaches such as hepatic arterial embolization or chemoembolization TACE or percutaneous ethanol injection PEI in the majority of patients who are either not candidates for surgical resection or are not offered palliative supportive care only for diffuse disease RFA can be applied repetitively to the same patient to treat multiple tumors at time of diagnosis or upon tumor recurrence local or distant to the site of ablation and is largely limited in its application only by tumor location and size tumors near larger vessels bowel or the hepatobiliary tree are more difficult to ablate To extend the volume of the ablation region in a controlled fashion in patients and to improve the ability to kill tumor cells in the ablation margin region and allow for the improved treatment of HCC and MLC lesions 3 cm in diameter by complete thermal ablation Celsion Corporation has developed ThermoDox a thermally sensitive intravenously administered liposomal formulation of doxorubicin capable of selectively releasing its drug contents when exposed to temperatures of 395C The concept behind this treatment approach is to create a large concentration gradient of doxorubicin in the immediate region of the tumor which borders the zone of RFA induced cell necrosis The temperature isotherms produced in this boundary region should be adequate to activate doxorubicin release by the thermally sensitive liposomes deposited locally around the ablation zone This in effect increases the region of tissue that can be treated beyond that achievable by RFA alone Several clinical objectives are being tested in this study The MTD for ThermoDox is to be confirmed This study will assess the safety of using ThermoDox in conjunction with RFA over multiple cycles consistent with the clinical needs of the subjects While this study is not powered to define effectiveness of the combination of RFA plus ThermoDox the results of this study should allow for an assessment of risk and benefit for designing future studies This study will also test alternative infusion reaction prophylaxis regimens
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None